U.S. regulators have restricted the sale of cheap copies of the drugs, slowing demand for raw ingredients Chinese firms ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

Teva Pharmaceuticals announced in late August 2025 that it received FDA approval and commenced the U.S. launch of its generic version of Saxenda® (liraglutide injection), which had annual sales of ...

Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs ...

President Donald Trump has plastered tariffs on products from almost every country on earth. He’s targeted specific imports ...

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.

These drugs can be divided into generic and biosimilar categories based on their composition. The generic segment is controlled by a few large drugmakers and generic units of large pharma companies.

A new study finds that drugmakers’ use of overlapping patents delayed generic entry for 4 top-selling drugs, driving billions in excess spending.

There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement ...

Consumers who purchased certain generic prescription drugs between May 2009 and December 2019 are eligible for compensation.